Trials / Completed
CompletedNCT03241264
A Study of Safety, Tolerability, and the Effects Two ND-L02-s0201 Have on the Body
A Phase 1, Open-Label, Randomized-Sequence, Single-Crossover, Bridging Study to Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Two ND-L02-s0201 Formulations, Frozen Versus Lyophilized, Administered by Intravenous Infusion to Healthy Male and Female Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and the effects two ND-L02-s0201 have on the body
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ND-L02-s0201 | Specified dose on specified day |
Timeline
- Start date
- 2016-08-28
- Primary completion
- 2016-10-21
- Completion
- 2016-10-21
- First posted
- 2017-08-07
- Last updated
- 2017-08-07
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03241264. Inclusion in this directory is not an endorsement.